Ribociclib (Kisqali, Novartis, Basel, Switzerland) is the second CDK4/6i receiving the FDA approval in March 2017 as the first line therapy for postmenopausal women with HR-positive, HER2-negative advanced, or metastatic BC in combination with an aromatase inhibitor (AI). Here, ERBB2 is linked to breast cancer.